<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">DiMarchi, Richard D.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Novel Oral Agents: The Search for Transformational Medicines</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">In 2011, 366 million people had diabetes; by 2030, that figure is projected to rise to 552 million [International Diabetes Federation. IDF Diabetes Atlas. 5th ed. 2009]. The search for novel oral antidiabetic drugs has taken on a growing sense of urgency. This article discusses efforts underway to develop glucagon-based incretin hybrids.</style></abstract><number><style face="normal" font="default" size="100%">16</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>